BILLERICA, Mass.--(BUSINESS WIRE)--Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.
